Applications
News & Events
Contact

EuLV™ became World's 1st LVV Stable Production System used in FDA IND approved CAR-T therapy

Date: 2025.01.16 Category: News Share:

We’re thrilled to share that Ucello Biotechnology's allogeneic CAR-T therapy (UC101), targeting CD19, has received FDA IND approval for clinical trials as of January 11th, 2025. This milestone is a major leap forward in the development of next-generation cell therapies!

EurekaBio's EuLV™ Technology Paves the Way for UC101's FDA Approval

UC101 has set a groundbreaking precedent as the first CAR-T therapy to utilize stable cell line for lentiviral vector production, earning it FDA IND approval. This innovation is powered by EurekaBio's cutting-edge EuLV™ LVV stable producer cell line production system.

 

EuLV™ system represents a significant leap forward in lentiviral vector production. Unlike traditional methods that rely on transient transfection and require the addition of DNA plasmids and transfection reagents, the EuLV™ system streamlines the process. This not only simplifies production but also slashes costs while enhancing the quality and consistency of viral vectors. The technology's serum-free suspension culture also facilitates easier scalability for lentiviral vector production.

Moreover, the EuLV™ system's stability and reliability guarantee the safety and uniformity of viral vectors throughout the manufacturing process, marking a significant advancement in the field.

 

The Transformative Power of Collaboration

Through our partnership with Ucello, the integration of EuLV™ system has significantly bolstered the research, development, and production of their allogeneic universal CAR-T cell therapy products. This collaboration enhances the efficiency of cell therapy production, ensuring it meets international quality standards while reducing costs. As a result, advanced CAR-T cell therapy is becoming more accessible to a broader range of patients.